Clinical trials are available for patients with an isocitrate dehydrogenase (IDH) mutation with hematologic malignancies and solid tumors
Committed to research
Inspired by patients and frustrated by the limitations of conventional approaches to cancer treatment, Agios is forging a new and different path to treating cancer by targeting cellular metabolism. Agios is committed to researching the role of IDH in cancer.
For more information about our clinical development programs, visit agios.com/pipeline/overview/.
Contact Agios Medical Affairs to learn more about Agios-sponsored clinical trials.